Stocks discussed in the in-depth session of Jim Cramer’s Mad Money TV program, Wednesday Aprill 11. Click on a stock ticker for more analysis:
Seeking Alpha publishes a summary of Jim Cramer's stock picks every day including: Mad Money Recap, Lightning Round, Stop Trading and his Wall Street Confidential Picks.
Cramer suggested three "horse racing stocks" under $10 to keep investors interested. These are just temporary plays and should be sold when they reach $12. He notes DYN was "trashed" because of its former CEO Chuck Watson, but has been rescued by current CEO Bruce Williamson. He notes that DYN could be an attractive takeover target. "Brocade has momentum but is scary -- which is exciting," Cramer said about his second-favorite pick, which recently bought out its competitor and is in a position to raise prices. Cramer's favorite "horse" is Qwest which is around $9, but should be the first to reach the finish line at $12, because of its big federal contract.
Related: Tiernan Ray asks if Brocade bought a lemon in McData.
Cramer discussed his favorite "aristocrat" stocks which pay solid dividends and provide protection when the economy is rough. He considered three "aristocrats," and eliminated WAG because it might have to stop raising its dividend to buy Express Scripts. While he expects GWW to boost its dividend, Cramer thinks the stock is too cyclical. Cramer's favorite artistocrat stock is ADP; "If there is such a thing as a blue chip, ADP is it." First, by spinning off its unprofitable brokerage service business, ADP may see 12-13% revenue growth. Secondly, Cramer likes ADP's "gigunda" $750 million buyback, and comments that ADP doesn't just have the history of raising its dividend, it has the money to continue dividend increases.
Related: Can ADP shake off Bad PR?
Cramer told a viewer not to get discouraged with LMC because it is buying up mines. He would pick up more LMC on any pullback. He commented DF is "going back to where it was before it paid the dividend" of $15, and says the company is well-managed and pro-shareholder. When asked to defend his recommendation of INCY, which has no phase III drugs, over a company like Osiris Therapeutics with products in the pipeline, Cramer responded the best strategy for dealing with biotech is to avoid companies in the headlines and to find a biotech like INCY which has " its whole future ahead of it."
Related: Analysts see upside in LMC.
Get Cramer's Picks by email -- it's free and takes only a few seconds to sign up.
Seeking Alpha is not affiliated with Jim Cramer, CNBC or TheStreet.com